Even though risk-adapted GVHD prophylaxis based on variations in graft composition is already considered, a better understanding of the mechanisms behind, and the consequences of, donor and graft heterogeneity is needed, including the possible roles of the IL-6 family and the contribution of G-CSF to the heterogeneity. This evidence concerns the gene IL6 and graft versus host disease.